What is GMP in pharma and why is it important

GMP (Good Manufacturing Practice) is the system of regulations, guidelines, and quality controls that ensures pharmaceutical products are consistently manufactured to the standard required for their intended use. It covers everything from raw materials and premises to staff training and documentation, and applies at every stage of production, not just final testing. For QA and GxP teams, GMP is the operating standard against which day-to-day work is measured, and the standard every regulatory inspection is conducted against.

What does GMP stand for and where does it come from?

GMP stands for Good Manufacturing Practice. In US regulatory language, you will most often see it written as cGMP – current Good Manufacturing Practice. The “c” is not decorative: it signals that manufacturers are expected to use systems, processes, and technologies that reflect current industry standards, not the standards in place when a facility was first validated. A quality system that was compliant a decade ago is not automatically compliant today.

GMP regulations were first introduced in the US in 1963, following a series of drug safety disasters, including the thalidomide tragedy, which exposed how inadequate manufacturing and testing controls could cause catastrophic harm. The World Health Organization published its first GMP guidelines in 1968, and the framework has since become the global standard for pharmaceutical manufacturing, adopted in various forms by regulators around the world.

What does GMP cover? The 10 core principles

GMP is best understood as ten interlocking principles, each covering a distinct part of the pharmaceutical operation. For QA and GxP readers, the table below works as a quick reference to come back to.

Principle	What it requires
People	Qualified, trained staff with defined roles and responsibilities
Premises & environment	Facilities designed to prevent contamination and cross-contamination
Equipment	Calibrated, maintained, and qualified for intended use
Documentation	Clear, accurate records of all processes, procedures, and outcomes
Production	Validated, controlled manufacturing processes with in-process checks
Quality control	Testing of materials and finished products before release
Quality assurance	Overarching system ensuring all GMP activities are performed correctly
Outsourced activities	Audited and controlled third-party suppliers and contract manufacturers
Compliance & recalls	Systems to investigate failures and withdraw defective products
Self-inspection	Regular internal audits to identify and correct GMP gaps

These ten principles are not siloed – in a functioning quality system, they interact constantly. A training gap under People can surface as a documentation error, which in turn triggers a deviation investigation under Compliance & recalls. This is why GMP is operationalized in practice through a Pharmaceutical Quality System (PQS): the structured framework that connects all ten principles into a single, auditable system rather than ten disconnected activities.

The quality unit – QA – is the function responsible for holding that system together. QA does not simply perform one of the ten activities; it has oversight of all of them, which is why its authority within the organization is a GMP requirement in its own right, not just good practice.

Why is GMP important in the pharmaceutical industry?

GMP compliance matters for three distinct but connected reasons.

Patient safety. Contamination, incorrect labeling, and incorrect active ingredient levels can cause serious harm or death. The thalidomide tragedy of the late 1950s and early 1960s, in which inadequate testing led to severe birth defects, remains the reason modern GMP regulation exists. More recently, heparin contaminated with an adulterated raw material sourced from China caused a wave of serious adverse reactions and deaths in the US in 2007-2008, and prompted significant tightening of raw material and supply chain controls under GMP. Both cases illustrate the same point: GMP failures are not administrative failures. They are patient safety failures.
Regulatory license to operate. Without GMP compliance, a manufacturer cannot legally produce or sell medicines in the UK, EU, or US. A GMP certificate is not a formality – it is the legal precondition for market access, and losing it is existential for a manufacturing site. Where a certificate is suspended or revoked, production stops immediately, regardless of contractual commitments to customers or patients waiting on supply.
Commercial integrity. Product recalls, warning letters, and import alerts are matters of public record, and they damage brand reputation well beyond their immediate financial cost. For QA teams, this is the practical reality behind the role: your work is the control point between a compliant operation and a finding that becomes public, names the organization, and follows it into every subsequent inspection and audit.

Who regulates GMP and which guidelines apply?

QA and GxP professionals are most likely to encounter three regulatory frameworks in their day-to-day work. This section is deliberately practical and comparative rather than exhaustive.

MHRA and EU GMP (UK and Europe)

In the UK, GMP is regulated by the MHRA under the Human Medicines Regulations 2012. UK GMP guidelines are set out in the Rules and Guidance for Pharmaceutical Manufacturers and Distributors, widely known across the industry as the “Orange Guide.” Since Brexit, UK GMP has remained closely aligned with EU GMP (EudraLex Volume 4), though divergences have started to emerge that QA teams operating across both markets need to actively monitor rather than assume away.

FDA and cGMP

In the US, cGMP is regulated by the FDA under 21 CFR Parts 210 and 211 for finished pharmaceuticals, with related requirements covering active pharmaceutical ingredients. FDA enforcement activity has intensified in recent years: fiscal year 2025 saw 112 warning letters citing cGMP violations under 21 CFR 211, the highest volume in more than two decades.

WHO GMP (global markets)

The WHO publishes internationally recognized GMP guidelines used by regulatory authorities in over 100 countries, particularly across low- and middle-income markets. Companies manufacturing for export into these markets, or sourcing from WHO-prequalified API suppliers, need to treat WHO GMP as a distinct framework in its own right, rather than assuming that MHRA or FDA compliance automatically satisfies it.

What is the role of the QA team in GMP compliance?

The quality unit occupies a unique position within a GMP-compliant organization: it is both a functional participant in day-to-day operations and an independent oversight function with authority that other departments cannot override.

In practice, this means QA must have the authority to approve or reject materials, intermediates, and finished products, and to halt production if GMP standards are not being met. This authority is not a courtesy extended by operations or manufacturing leadership – it is a GMP requirement. An inspector who finds that QA’s decisions can be overridden by commercial or production pressure will treat that as a fundamental quality system failure, regardless of how well individual procedures are documented.

What are the common challenges of GMP compliance?

The reality of GMP compliance today is that it is not easy, and the challenges are largely structural rather than a matter of individual effort.

Error-prone manual processes: many QA and GxP teams still rely on spreadsheets, shared drives, and disconnected tools to manage surveillance and impact assessments. These workarounds are difficult to maintain, hard to scale, and vulnerable under inspection pressure.
No consistent way to capture expert input: impact assessments often depend on feedback from multiple subject matter experts, but without a harmonized way to collect, track, and reconcile responses. This creates inconsistency, delays, and unnecessary risk.
Lack of accountability and follow-through: when actions are managed across emails and documents, there is no clear ownership, no structured reminders, and no reliable way to show who did what or when.
Fear of missing a critical update: with growing volumes of regulatory change, teams operate with the constant anxiety that something important may have been delayed, overlooked, or misinterpreted.
High-stakes consequences: missed or poorly handled updates can be flagged during inspections, leading to operational shutdowns, delayed launches, and, in some cases, legal action. Being compliant isn’t enough – you need to be able to demonstrate how you responded to new or updated guidance, clearly, consistently, and with evidence.

What happens if GMP compliance fails?

For QA and GxP teams, failure isn’t abstract. When regulatory updates are missed, poorly assessed, or inadequately documented, the consequences surface quickly – often during an inspection, when there is no time to reconstruct decisions after the fact.

Operational shutdowns. In GMP environments, unaddressed or poorly handled findings can halt operations at a specific site. Even a temporary shutdown carries significant operational, financial, and reputational impact.
Delayed product launches. In clinical and GCP contexts, missing or misinterpreting regulatory intelligence can delay submissions and approvals. The result is a slower time to market, disrupted development timelines, and lost revenue.
Legal and regulatory exposure. The risk is not theoretical. Organizations have faced criminal and civil liability after failing to maintain GMP-compliant manufacturing operations. Without a clear, defensible record, teams are left exposed when decisions are challenged.

The consequences of GMP failure also tend to escalate in a fairly predictable order:

483 observations (FDA) or GMP deficiencies (MHRA): recorded during an inspection; both require a written response and CAPA plan, typically within a defined window.
Warning letters: formal notice that violations are serious. FDA issued 112 warning letters citing cGMP violations in fiscal year 2025 – the highest number in over 20 years ^1* – and production may need to cease for affected products while issues are resolved.
Import alerts: block a product from entering a market entirely, with significant and immediate commercial impact on supply.
License suspension or revocation: the GMP certificate is withdrawn and manufacturing at the site must stop.
Product recall: defective product already in the market is removed, at significant cost and reputational damage.
Criminal prosecution: reserved for the most serious or repeated failures. The clearest illustration remains a 2010 case in which a GSK manufacturing subsidiary pleaded guilty to a felony charge under the US Food, Drug and Cosmetic Act over cGMP violations at a Puerto Rico plant, resulting in $750 million in combined criminal and civil penalties – a reminder that GMP failures can carry consequences well beyond a single inspection cycle.

GMP documentation

Documentation is not administrative overhead – it is the evidentiary foundation of GMP. If it is not documented, it did not happen. This is the operative principle regulators apply, and it means that a GMP-compliant activity performed but not properly recorded is, from an inspection standpoint, indistinguishable from an activity that never took place.

QA teams manage a wide range of document types as part of routine GMP operations, including:

Standard operating procedures (SOPs)
Batch manufacturing records (BMRs)
Batch packaging records
Specifications
Validation protocols and reports
Change control records
Deviation and CAPA logs
Training records

Data integrity, assessed against the ALCOA+ principles – attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, and available – is the MHRA’s top enforcement priority, accounting for nearly 40% of critical GMP deficiencies. Strong documentation practices are what make ALCOA+ achievable as part of daily operation, rather than an exercise reserved for audit week.

Frequently asked questions about GMP in pharma

What is the difference between GMP and cGMP?

GMP and cGMP refer to the same underlying principles; the “c,” for “current,” specifies that manufacturers must use systems, equipment, and controls that reflect present-day standards, not the standards in place when a facility was originally validated. In US regulation, cGMP is the term used in law; elsewhere, the terms are often used interchangeably.

Who is responsible for GMP compliance in a pharmaceutical company?

GMP compliance is a shared responsibility across the organization, but the quality unit (QA) holds ultimate authority and accountability. QA must be able to approve, reject, or halt any activity that does not meet GMP standards, independent of production or commercial pressure.

What happens if a company fails a GMP audit?

Outcomes depend on the severity of the findings. Minor findings typically require a documented CAPA plan, while critical findings can lead to a warning letter, import alert, or suspension of the site’s manufacturing license until corrective actions are verified.

Is GMP a legal requirement in the UK?

Yes. GMP compliance is a legal requirement in the UK under the Human Medicines Regulations 2012, enforced by the MHRA. A manufacturer without a valid GMP certificate cannot legally manufacture or supply medicines for the UK market.

How Infodesk supports GMP compliance

GMP compliance is a daily operational challenge for QA and GxP teams, not a one-time project. Infodesk makes it manageable: regulatory intelligence surveillance – including inspection and enforcement intelligence – is combined with the ability to turn that intelligence into decisions and action, within a single platform that also monitors other enterprise intelligence streams and integrates with workflow tools for immediate outcomes. Infodesk supports quality, GMP, audit, and inspection and enforcement teams across the full compliance cycle, from preparing for regulatory change to handling inspections, responding to findings, and staying ahead of enforcement risk. every inspector profile, every 483, every warning letter, across seven global regulators, with an AI Assistant that turns raw data into analysis you can act on immediately, all in one place. Learn more about how Infodesk helps QA and GxP teams.

Learn more about inspection & enforcement intelligence from Infodesk.

GMP intelligence. Activated.

Ready to strengthen your inspection readiness program? Want to learn more about GMP intelligence surveillance for inspections and enforcement? Talk to us to find out how.

*Cited sources